4.7 Article

Anti-voltage-gated potassium channel Kv1.4 antibodies in myasthenia gravis

Related references

Note: Only part of the references are listed.
Article Clinical Neurology

Matrix Metalloproteinases in Myasthenia Gravis

Geir Helgeland et al.

EUROPEAN NEUROLOGY (2011)

Article Immunology

Clinical and immunological differences between early and late-onset myasthenia gravis in Japan

Shigeaki Suzuki et al.

JOURNAL OF NEUROIMMUNOLOGY (2011)

Review Clinical Neurology

Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity

Matthew N. Meriggioli et al.

LANCET NEUROLOGY (2009)

Article Clinical Neurology

Ocular myasthenia: diagnostic and treatment recommendations and the evidence base

Uladzimir Luchanok et al.

CURRENT OPINION IN NEUROLOGY (2008)

Article Immunology

Serum matrix metalloproteinase-3 levels are elevated in myasthenia gravis

Fredrik R. Romi et al.

JOURNAL OF NEUROIMMUNOLOGY (2008)

Article Clinical Neurology

Clinical spectrum of voltage-gated potassium channel autoimmunity

K. M. Tan et al.

NEUROLOGY (2008)

Article Clinical Neurology

Detection and characterization of MuSK antibodies in seronegative myasthenia gravis

J McConville et al.

ANNALS OF NEUROLOGY (2004)

Review Multidisciplinary Sciences

The voltage-gated potassium channels and their relatives

G Yellen

NATURE (2002)

Article Clinical Neurology

Therapeutic options in ocular myasthenia gravis

A Evoli et al.

NEUROMUSCULAR DISORDERS (2001)